Account
Inquiry
Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes treatment and weight management research. This innovative peptide demonstrates superior efficacy in glucose control and weight reduction compared to similar compounds.
The molecular structure of Tirzepatide features a PEG-modified lysine side chain that enhances water solubility while maintaining biological activity. As a dual agonist, it exhibits greater affinity for GIP receptors than GLP-1 receptors, producing more significant reductions in hyperglycemia.
Clinical studies have demonstrated Tirzepatide's effectiveness in weight management. In the SURMOUNT-1 trial, participants achieved average weight reductions of 15-20.9% over 72 weeks depending on dosage (5mg, 10mg, or 15mg weekly). The compound has received FDA Fast Track designation for obesity treatment applications.
For research purposes, we offer Tirzepatide in high purity (99.9%) white powder form. The product is carefully packaged to maintain stability and potency throughout storage and transportation.
As a manufacturer specializing in peptide compounds, we maintain strict quality control standards throughout production. Our facilities are equipped to handle both small-scale and bulk orders, with customization options available for specific research requirements.
Note: This product is intended for research use only. Not for human consumption or diagnostic use. Proper storage conditions are essential to maintain peptide integrity - keep in a cool, dry, dark environment and avoid repeated freeze-thaw cycles.
